Thread by @TumorBoardTues

1/ 🌟 Calling #Oncology HCPs 🌟

🆕 #TumorBoardTuesday #Tweetorial #GI22
🧬 HER2 in Gastrointestinal Cancer
👥 @MPishvaian @BenWestphalen

Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.

CME ℹ️ bit.ly/3ruGO07

⁉️ Your specialty

2/ 🗒️ Full reference list & glossary 👉 bit.ly/3tBrmC7

🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ruGO07

#TumorBoardTuesday #GI22

3/ 🛑 POLL 🛑

🤔 How frequently do you currently employ emerging novel therapies & clinical trial enrollment for your patients ❓
#TumorBoardTuesday #GI22

4/ 🛑 POLL 🛑

🤔 What 💊 Tx would you recommend for a 🧑 patient w/ 🧬 HER2 ➕ GC & progression on a trastuzumab-containing regimen ❓
#TumorBoardTuesday #GI22

5/ ✅ Approved 💊 Txs for 🧬 HER2 ➕ unresectable LA or m GC/GEC

1⃣st-line
👉 (Fluorouracil or capecitabine) & (oxaliplatin or cisplatin) & trastuzumab ±/- pembrolizumab
#TumorBoardTuesday #GI22

6/ ✅ Approved Txs for 🧬 HER2 ➕ unresectable LA or m GC/GEC

2⃣nd- & subsequent lines
👉 Paclitaxel ± ramucirumab
👉 Docetaxel
👉 Ramucirumab
👉 Irinotecan/FOLFIRI ± ramucirumab
👉 Pembro/nivo (GEC only)
👉 T-DXd
👉 Trifluridine + tipiracil
#TumorBoardTuesday #GI22

7/ 🗒️ Open-label, Ph2 trial evaluating 1st-line trastuzumab ➕ pembro ➕ chemo in 37 🧑 patients w/ 🧬 HER2 ➕ m EC, GC, or GEC

💡 Conclusion: the combination of trastuzumab ➕ pembro is safe & active in treating mEC
#TumorBoardTuesday #GI22

8/ DESTINY-Gastric01

🗒️ Open-label, Ph2 trial
🔎 T-DXd 🆚 chemo
🧑 187 Asian patients w/ aGC/GEC & progression on 2+ prior therapies including trastuzumab

📌T-DXd: significant improvements in response & OS
👉Notable toxicities
👉Myelosuppression
🫁 ILD
#TumorBoardTuesday #GI22

9/ ‼️ 🧬 HER2-targeted 🎯 agents under 🔎 investigation in GC/GEC

👉 T-DXd
👉 Tucatinib
👉 Margetuximab
👉 ARX788
#TumorBoardTuesday #GI22

10/ 📌 DESTINY-Gastric04:

🗒️ Open-label, Ph3 trial evaluating
💊T-DXd 🆚 ramucirumab ➕ paclitaxel in 490 🧑 patients w/ prev treated 🧬 HER2 ➕ m &/or unresectable GC/GEC

🥅 Goal: assess efficacy & safety of T-DXd

👉 Status: recruiting
#TumorBoardTuesday #GI22

11/ 📌 MOUNTAINEER-02:

🗒️ Double-blind, Ph3 trial evaluating
💊Ramucirumab/paclitaxel ± tucatinib/trastuzumab in 578 🧑 patients w/ prev 🧪 treated, LA unresectable or m 🧬 HER2 ➕ GC/GEC

🥅Determine superiority of tucatinib/trastuzumab

👉Recruiting
#TumorBoardTuesday #GI22

12/ 🛑 POLL 🛑

🤔 Which 🧬 HER2-targeted 🎯 agent is being evaluated in combination w/ anti-PD-1 ± anti-LAG-3 monoclonal antibodies for the 🥇 first-line 💊 Tx of 🧑 patients w/ GC/GEC ❓
#TumorBoardTuesday #GI22

13/ ✅ Margetuximab #TumorBoardTuesday

📌 MAHOGANY
🗒️ Open-label, Ph2/3 trial
💊margetuximab ➕ chemo ± (retifanlimab or tebotelimab) 🆚 trastuzumab ➕ chemo in prev unTx 🧬HER2➕ LA unresectable or mGC/GEC

🥅 Determine efficacy of anti-HER2/PD-1± anti LAG-3 Tx
👉 Recruiting

14/ 🧬 HER2-targeted 🎯 agents under 🔎 investigation in CRC

📌 Trastuzumab ➕ (lapatinib, pertuzumab, or tucatinib)
📌 Trastuzumab deruxtecan
#TumorBoardTuesday #GI22

15/ 🧬 HER2-targeted 🎯 agents under 🔎 investigation in biliary tract cancers

📌 Trastuzumab ➕ pertuzumab
#TumorBoardTuesday #GI22

16/ 🔑 🔑 🔑 Key points ‼️ #TumorBoardTuesday #GI22

FDA-approved ✅ agents are under 🔎 investigation for use in:
📌 Earlier lines of therapy for GC/GEC: T-DXd
📌 GC/GEC: margetuximab (1st-line) & tucatinib (2nd-line)

🌟 Earliest primary completion: April 2024 (T-DXd) 🌟

17/ Thank you 🙏 for Joining this HER2 in Gastrointestinal Cancer #TumorBoardTuesday #Tweetorial #GI22

👉 Knowledge on the go - 🆓 resources: integrityce.com/HER2resources

‼️ Pick up your #CME 👉 by answering 3 quick questions 🧠 ❓
💥 Voila 💥

18/ #Posttest Q 1⃣ #CME #TumorBoardTuesday #GI22

🤔 How frequently do you now plan to employ emerging novel therapies & clinical trial enrollment for your patients ❓

Claim Credit: bit.ly/3qCpfMs

19/ #Posttest Q 2⃣ #CME #TumorBoardTuesday #GI22

🤔 What 💊 Tx would you recommend for a 🧑 patient w/ 🧬 HER2 ➕ GC & progression on a trastuzumab-containing regimen ❓

Claim Credit: bit.ly/3qCpfMs

20/ #Posttest Q 3⃣ #CME #TumorBoardTuesday #GI22

🤔 Which 🧬 HER2-targeted 🎯 agent is being evaluated in combination w/ anti-PD-1 ± anti-LAG-3 monoclonal antibodies for the 🥇 first-line 💊 Tx of 🧑 patients w/ GC/GEC ❓

Claim Credit: bit.ly/3qCpfMs

21/ 🙏 for joining this #TumorBoardTuesday #Tweetorial #GI22

👉 Knowledge on the go - 🆓 resources: integrityce.com/HER2resources

💥 Stay tuned for more from @TumorBoardTues

➡️ Now weigh in on tonight's #PancChat ‼️ ⬅️

@letswinpc @PanCAN @MPishvaian